Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: Future reality or Utopia?

Annals of the New York Academy of Sciences

Volumn 1171, Issue , 2009, Pages 228-241

  Wȩsierska Ga̧dek, Józefa ^a   Kryštof, Vladimír ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Cell cycle; CYC202; Cyclin dependent kinase; p53; Roscovitine; Transcription

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; H 717; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; OLOMOUCINE; OLOMOUCINE II; PURVALANOL B; ROSCOVITINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL STRESS; CELLULAR STRESS RESPONSE; CONFERENCE PAPER; DRUG MECHANISM; DRUG TARGETING; ENZYME ANALYSIS; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; NONHUMAN; TRANSCRIPTION REGULATION;

EID: 69149090005     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04726.x     Document Type: Conference Paper

References (86)

1. Norbury, C. P. Nurse. 1992. Animal cell cycles and their control. Annu. Rev. Biochem. 61 : 441 470.
2. Van Den Heuvel, S. E. Harlow. 1993. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262 : 2050 2054.
3. Jacks, T. R.A. Weinberg. 1998. The expanding role of cell cycle regulators. Science 280 : 1035 1036.
4. Nakayama, K.I. K. Nakayama. 2006. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 6 : 369 381.
5. Diehl, J.A., M. Cheng, et al. 1998. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12 : 3499 3511.
6. Alt, J.R., J.L. Cleveland, et al. 2000. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 14 : 3202 3214.
7. Lin, D.I., M.D. Lessie, et al. 2008. Disruption of cyclin D1 nuclear export and proteolysis accelerated mammary carcinogenesis. Oncogene 27 : 1231 1242.
8. LeCam, L., J. Polanowska, et al. 1999. Timing of cyclin E gene expression depends on the regulated association of a bipartite repressor element with a novel E2F complex. EMBO J. 18 : 1878 1890.
9. Dahiya, A., S. Wong, et al. 2003. Linking the Rb and polycomb pathways. Mol. Cell 11 : 1693 1696.
10. Zhu, W., P. H. Giangrande J. R. Nevins. 2004. E2Fs link the control of G1/S and G2/M transcription. EMBO J. 23 : 4615 4626.
11. Bolognese, F., M. Wasner, et al. 1999. The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated. Oncogene 18 : 1845 1853.
12. Mantovani, R. 1999. The molecular biology of the CCAAT-binding factor NF-Y. Gene 239 : 15 27.
13. Wasner, M., U. Haugwitz, et al. 2003. Three CCAAT-boxes and a single cell cycle genes homology region (CHR) are the major regulating sites for transcription from the human cyclin B2 promoter. Gene 312 : 225 237.
14. Salsi, V., G. Caretti, et al. 2003. Interactions between p300 and multiple NF-Y trimers govern Cyclin B2 promoter function. J. Biol. Chem. 278 : 6642 6650.
15. Fisher, R.P. 2005. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J. Cell Sci. 118 : 5171 5180.
16. Jeffrey, P.D., A.A. Russo, et al. 1995. Mechanism of CDK activation revealed by a structure of a cyclin A-CDK2 complex. Nature 376 : 313 320.
17. Russo, A.A., P.D. Jeffrey N.P. Pavletich. 1996. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. 3 : 696 700.
18. Morgan, D.O. 1995. Principles of CDK regulation. Nature 374 : 131 134.
19. Sherr, C.J. J.M. Roberts. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13 : 1501 1512.
20. Senderowicz, A.M. 2003. Small-molecule cyclin-dependent kinase modulators. Oncogene 22 : 6609 6620.
21. Weinberg, R.A. 1996. The molecular basis of carcinogenesis: understanding the cell cycle clock. Cytokines Mol. Ther. 2 : 105 110.
22. Palancade, B. O. Bensaude. 2003. Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation. Eur. J. Biochem. 270 : 3859 3870.
23. Meinhart, A., T. Kamenski, et al. 2005. A structural perspective of CTD function. Genes Dev. 19 : 1401 1415.
24. Marshall, R.M. X. Grana. 2006. Mechanisms controlling CDK9 activity. Front. Biosci. 11 : 2598 2613.
25. Fesquet, D., J.C. Labbé, et al. 1993. The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues. EMBO J. 12 : 3111 3121.
26. Poon, R.Y., K. Yamashita, et al. 1993. The cdc2-related protein p40MO15 is the catalytic subunit of a protein kinase that can activate p33cdk2 and p34cdc2. EMBO J. 12 : 3123 3132.
27. Solomon, M.J., J.W. Harper J. Shuttleworth. 1993. CAK, the p34cdc2 activating kinase, contains a protein identical or closely related to p40MO15. EMBO J. 12 : 3133 3142.
28. Devault, A., A.M. Martinez, et al. 1995. MAT1 ('menage à trois') a new RING finger protein subunit stabilizing cyclin H-cdk7 complexes in starfish and Xenopus CAK. EMBO J. 14 : 5027 5036.
29. Brown, A.J., T. Jones J. Shuttleworth. 1994. Expression and activity of p40MO15, the catalytic subunit of cdk-activating kinase, during Xenopus oogenesis and embryogenesis. Mol. Biol. Cell. 5 : 921 932.
30. Matsuoka, M., J.Y. Kato, et al. 1994. Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. Mol. Cell Biol. 14 : 7265 7275.
31. Larochelle, S., J. Chen, et al. 2001. T-loop phosphorylation stabilizes the CDK7-cyclin H-MAT1 complex in vivo and regulates its CTD kinase activity. EMBO J. 20 : 3749 3759.
32. Larochelle, S., K.A. Merrick, et al. 2007. Requirements for Cdk7 in the assembly of cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol. Cell 25 : 839 850.
33. Rossi, D.J., A. Londesborough, et al. 2001. Inability to enter S phase and defective RNA polymerase II CTD phosphorylation in mice lacking Mat1. EMBO J. 20 : 2844 2856.
34. Schneider, E., S. Kartarius, et al. 2002. The cyclin H/cdk7/Mat1 activity is regulated by CK2 phosphorylation of cyclin H. Oncogene 21 : 5031 5037.
35. Schneider, E., M. Montenarh P. Wagner. 2002. Regulation of CAK kinase activity by p53. Oncogene 17 : 2733 2741.
36. Vesely, J., L. Havlicek, et al. 1994. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224 : 771 786.
37. Havlicek, L., J. Hanus, et al. 1997. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem. 40 : 408 412.
38. Meijer, L., A. Borgne, et al. 1997. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243 : 527 536.
39. Legraverend, M. D.S. Grierson. 2006. The purines: potent and versatile small molecule inhibitors and modulators of key biological targets. Bioorg. Med. Chem. 14 : 3987 4006.
40. Meijer, L. E. Raymond. 2003. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res. 36 : 417 425.
41. Bach, S., M. Knockaert, et al. 2005. Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem. 280 : 31208 31219.
42. Fabian, M.A., W.H. Biggs, 3rd., et al. 2005. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23 : 329 336.
43. Canduri, F., H.B. Uchoa W.F. de Azevedo, Jr. 2004. Molecular models of cyclin-dependent kinase 1 complexed with inhibitors. Biochem. Biophys. Res. Commun. 324 : 661 666.
44. McClue, S.J., D. Blake, et al. 2002. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 102 : 463 468.
45. Krystof, V., I.W. McNae, et al. 2005. Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell. Mol. Life Sci. 62 : 1763 1771.
46. Grisendi, S., C. Mecucci, et al. 2006. Nucleophosmin and cancer. Nat. Rev. Cancer 6 : 493 505.
47. Chen, Y.N., S.K. Sharma, et al. 1999. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Sci. USA 96 : 4325 4329.
48. Cai, D., V.M. Latham, Jr., et al. 2006. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res. 66 : 9270 9280.
49. Zhang, G.J., M. Safran, et al. 2004. Bioluminescent imaging of Cdk2 inhibition in vivo. Nat. Med. 10 : 643 648.
50. Kotala, V., S. Uldrijan, et al. 2001. Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases. Cell. Mol. Life Sci. 58 : 1333 1339.
51. Lu, W., L. Chen, et al. 2001. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 20 : 3206 3216.
52. Whittaker, S.R., M.I. Walton, et al. 2004. The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res. 64 : 262 272.
53. Lacrima, K., A. Valentini, et al. 2005. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann. Oncol. 16 : 1169 1176.
54. Whittaker, S.R., R.H. Te Poele, et al. 2007. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. Cell Cycle 6 : 3114 3131.
55. Ljungman, M. M.T. Paulsen. 2001. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol. Pharmacol. 4 : 785 789.
56. Chao, S.H., K. Fujinaga, et al. 2000. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275 : 28345 28348.
57. Demidenko, Z.N. M.V. Blagosklonny. 2004. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res. 64 : 3653 3660.
58. Somesh, B.P., J. Reid, et al. 2005. Multiple mechanisms confining RNA polymerase II ubiquitylation to polymerases undergoing transcriptional arrest. Cell 121 : 913 923.
59. Kim, E.H., S.U. Kim, et al. 2004. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 23 : 446 456.
60. MacCallum, D.E., J. Melville, et al. 2005. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65 : 5399 5407.
61. Raje, N., S. Kumar, et al. 2005. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 106 : 1042 1047.
62. David-Pfeuty, T. 1999. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. Oncogene 18 : 7409 7422.
63. Wojciechowski, J., M. Horky, et al. 2003. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int. J. Cancer 106 : 486 495.
64. Mohapatra, S., D. Coppola, et al. 2007. Roscovitine inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma. Mol. Cancer Res. 5 : 145 151.
65. Teodoro, J.G., S.K. Evans M.R. Green. 2007. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J. Mol. Med. 85 : 1175 1186.
66. Dey, A., E.T. Wong, et al. 2008. R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ. 15 : 263 273.
67. Wesierska-Gadek, J., M. Gueorguieva M. Horky. 2005. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol. Cancer Ther. 4 : 113 124.
68. Gomes, N.P., G. Bjerke, et al. 2006. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev. 20 : 601 612.
69. Barboric, M., R.M. Nissen, et al. 2001. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol. Cell 8 : 327 337.
70. Eberhardy, S.R. P.J. Farnham. 2002. Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. J. Biol. Chem. 277 : 40156 40162.
71. White, R.J. 2005. RNA polymerases I and III, growth control and cancer. Nat. Rev. Mol. Cell. Biol. 6 : 69 78.
72. Sirri, V., D. Hernandez-Verdun P. Roussel. 2002. Cyclin-dependent kinases govern formation and maintenance of the nucleolus. J. Cell Biol. 156 : 969 981.
73. Voit, R. I. Grummt. 2001. Phosphorylation of UBF at serine 388 is required for interaction with RNA polymerase I and activation of rDNA transcription. Proc. Natl. Acad. Sci. USA 98 : 13631 13636.
74. Hannan, K.M., R.D. Hannan, et al. 2000. Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1. Oncogene 19 : 4988 4999.
75. Chu, W.M., Z. Wang, et al. 1997. RNA polymerase III transcription repressed by Rb through its interactions with TFIIIB and TFIIIC2. J. Biol. Chem. 272 : 14755 14761.
76. Chesnokov, I., W.M. Chu, et al. 1996. p53 inhibits RNA polymerase III-directed transcription in a promoter-dependent manner. Mol. Cell. Biol. 16 : 7084 7088.
77. Pestov, D.G., Z. Strezoska L.F. Lau. 2001. Evidence of p53-dependent cross-talk between ribosome biogenesis and the cell cycle: effects of nucleolar protein Bop1 on G(1)/S transition. Mol. Cell. Biol. 21 : 4246 4255.
78. De Azevedo, W.F. Jr., F. Canduri N.J. da Silveira. 2002. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem. Biophys. Res. Commun. 293 : 566 571.
79. McGrath, C.F., N. Pattabiraman, et al. 2005. Homology model of the CDK1/cyclin B complex. J. Biomol. Struct. Dyn. 22 : 493 502.
80. De Azevedo, W.F., S. Leclerc, et al. 1997. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243 : 518 526.
81. Rossi, K.A., J.A. Markwalder, et al. 2005. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors. J. Comput. Aided Mol. Des. 19 : 111 122.
82. Honma, T., T. Yoshizumi, et al. 2001. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. J. Med. Chem. 44 : 4628 4640.
83. Lu, H. U. Schulze-Gahmen. 2006. Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition. J. Med. Chem. 49 : 3826 3831.
84. Santamaría, D., C. Barrière, et al. 2007. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448 : 811 815.
85. Frantz, S. 2005. Drug discovery: playing dirty. Nature 437 : 942 943.
86. Shapiro, G.I. 2006. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24 : 1770 1783.